VRTX vs SRPT Stock Comparison: AI Score, Valuation, Performance and Upside
Vertex Pharmaceuticals is generally evaluated as a diversified, highly profitable biotech with a dominant cystic fibrosis franchise, while Sarepta Therapeutics is assessed as a more concentrated gene therapy company navigating safety-related setbacks in its Duchenne muscular dystrophy franchise. The comparison contrasts a stable, diversified profit engine against a higher-risk, more concentrated rare disease specialist.
Use this comparison to weigh Vertex's diversified, established profitability against Sarepta's concentrated Duchenne muscular dystrophy franchise and its associated safety and execution risks.
VRTX holds the edge across 4 of 5 key metrics in this comparison. VRTX has delivered stronger 1-year price return (+24.72% vs -19.86%), though SRPT has the better forward P/E setup (9.03x vs 24.63x for VRTX). VRTX leads on both revenue growth (12.50%) and operating margin (38.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for VRTX (+3.96%) than for SRPT (-4.09%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to an established, highly profitable, diversified biotech franchise
- Prefer lower binary clinical and safety risk than concentrated rare disease specialists
- Value a strong balance sheet funding ongoing pipeline diversification
- Are comfortable with a premium valuation reflecting franchise quality
- Believe Sarepta can stabilize its Duchenne muscular dystrophy franchise after past safety setbacks
- Want concentrated exposure to gene therapy in a defined rare disease category
- Are comfortable with elevated regulatory and reimbursement scrutiny
- See potential value in a depressed valuation relative to prior peak levels
| Metric | VRTX | SRPT |
|---|---|---|
| AI scorei | 56.4 | 23.8 |
| AI ranki | #142 | #3147 |
| Latest closei | $508.75 | $17.79 |
| 1M returni | -1.14% | -14.14% |
| 3M returni | +4.67% | +3.25% |
| 6M returni | +16.78% | -15.97% |
| 1Y returni | +24.72% | -19.86% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | SRPT |
|---|---|---|
| 1Y ago | $12.45K (+24.5%) started 2025-10-16 | $7.62K (-23.8%) started 2025-10-16 |
| 5Y ago | $28.14K (+181.4%) started 2021-10-18 | $2.19K (-78.1%) started 2021-10-18 |
| 10Y ago | $63.2K (+532.0%) started 2016-10-17 | $3.64K (-63.6%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | VRTX | SRPT |
|---|---|---|
| Market capi | $137.3B | $2.45B |
| Trailing P/Ei | 31.55 | N/A |
| Forward P/Ei | 24.63 | 9.03 |
| Price/Salesi | 10.42 | N/A |
| EV/Revenuei | 10.44 | 1.28 |
| Analyst targeti | $563.12 | $22.26 |
| Target upsidei | +3.96% | -4.09% |
| Metric | VRTX | SRPT |
|---|---|---|
| Revenue growthi | 12.50% | -34.30% |
| Earnings growthi | 8.00% | N/A |
| EPS growthi | +8.00% | N/A |
| FCF margini | +20.88% | +1.12% |
| Operating margini | 38.05% | 13.03% |
| Profit margini | 35.00% | -6.93% |
| ROIC proxyi | 23.54% | -9.48% |
| Return on equityi | 23.54% | -9.48% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.30 | 0.20 |
| Debt/equityi | 9.77 | 69.54 |
| Current ratioi | 3.19 | 4.42 |
| Quick ratioi | 2.54 | 2.44 |
Over the past year, VRTX and SRPT have moved weakly in the same direction (correlation of 0.31), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | VRTX | SRPT |
|---|---|---|---|
| 1Y | Growthi | +24.51% | -23.78% |
| CAGRi | +24.55% | -23.81% | |
| Volatilityi | 28.78% | 78.99% | |
| Sharpe ratioi | 0.75 | 0.00 | |
| Sortino ratioi | 1.21 | 0.00 | |
| Max drawdowni | 15.21% | 39.22% | |
| Current drawdowni | 8.82% | 27.24% | |
| Avg drawdowni | 6.08% | 20.90% | |
| Ulcer Indexi | 7.63% | 23.17% | |
| Max daily dropi | 4.56% | 33.74% | |
| Max wkly dropi | 9.32% | 33.11% | |
| 5Y | Growthi | +181.39% | -78.10% |
| CAGRi | +23.02% | -26.22% | |
| Volatilityi | 29.07% | 70.15% | |
| Sharpe ratioi | 0.71 | -0.12 | |
| Sortino ratioi | 0.99 | -0.17 | |
| Max drawdowni | 29.07% | 92.72% | |
| Current drawdowni | 8.82% | 89.14% | |
| Avg drawdowni | 7.32% | 39.62% | |
| Ulcer Indexi | 9.61% | 51.50% | |
| Max daily dropi | 20.60% | 42.12% | |
| Max wkly dropi | 20.71% | 47.84% | |
| 10Y | Growthi | +531.99% | -63.65% |
| CAGRi | +20.25% | -9.63% | |
| Volatilityi | 32.61% | 65.69% | |
| Sharpe ratioi | 0.59 | 0.13 | |
| Sortino ratioi | 0.88 | 0.18 | |
| Max drawdowni | 41.60% | 93.33% | |
| Current drawdowni | 8.82% | 90.05% | |
| Avg drawdowni | 10.89% | 39.55% | |
| Ulcer Indexi | 14.64% | 47.30% | |
| Max daily dropi | 20.70% | 51.29% | |
| Max wkly dropi | 22.29% | 51.73% |
| Category | VRTX | SRPT |
|---|---|---|
| Company | Vertex Pharmaceuticals Incorporated | Sarepta Therapeutics, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Vertex Pharmaceuticals develops and markets therapies for cystic fibrosis and is expanding into pain management, diabetes, and gene-editing treatments through its clinical pipeline. | Sarepta Therapeutics develops precision genetic medicines, including RNA-based and gene therapy treatments, primarily focused on Duchenne muscular dystrophy and other rare neuromuscular diseases. |
| Investor focus | Investors watch cystic fibrosis franchise durability, commercial uptake of newer non-opioid pain and gene-editing therapies, and pipeline diversification progress. | Investors track commercial sales trends for its gene therapy and exon-skipping treatments, safety monitoring following prior adverse event disclosures, and pipeline progress in additional neuromuscular indications. |
- Dominant, highly profitable franchise in cystic fibrosis treatments
- Strong balance sheet funding pipeline diversification efforts
- Approved gene-editing and non-opioid pain therapies expanding beyond core franchise
- Leading position in Duchenne muscular dystrophy treatment with multiple approved therapies
- First-mover gene therapy experience in a difficult-to-treat rare disease
- Pipeline extending precision genetic medicine approach to related neuromuscular conditions
- Long-term reliance on cystic fibrosis franchise for the bulk of revenue
- New therapy launches carry commercial execution and reimbursement risk
- Patent and competitive dynamics in core disease areas over time
- Safety concerns have previously affected gene therapy commercial momentum and investor sentiment
- Revenue concentration in a narrow set of neuromuscular disease therapies
- Regulatory and reimbursement scrutiny following safety-related disclosures
Compare more than two at a time
This page is a fixed writeup on VRTX and SRPT. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside VRTX and SRPT, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.